B. Riley Securities Reiterates Buy on Altimmune, Lowers Price Target to $11
Benzinga Newsdesk 5 hours ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst William Woods reiterates Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $13 to $11.
B. Riley Securities analyst William Woods reiterates Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $13 to $11.